Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 8/20 | 0.96 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 8/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | THRB | P10828 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | DRD3 | P35462 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen SCHEMBL1417519 | 1.00 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL351220 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.96 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL2996117 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL3004536 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL22352888 | 0.92 | GABBR2 (0.87) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119776295-A | Olefin reductase, coding gene, vector, engineering bacteria and application thereof | 浙江工业大学 | 2025-04-08 | — | — | CN | claimed |
| US-20220016061-A1 | Preparation Stabilized by Means of Nonaqueous Solvent | MEDRX CO., LTD. (JP) | 2022-01-20 | — | — | US | claimed |
| EP-3861993-A1 | PREPARATION STABILIZED BY MEANS OF NONAQUEOUS SOLVENT | MEDRx Co., Ltd. (JP) | 2021-08-11 | — | — | EP | claimed |
| CN-113164423-A | Formulations stabilized with non-aqueous solvents | 美德阿利克斯株式会社 | 2021-07-23 | — | — | CN | claimed |
| WO-2020071546-A1 | PREPARATION STABILIZED BY MEANS OF NONAQUEOUS SOLVENT | 株式会社 メドレックス | 2020-04-09 | — | — | WO | claimed |
| US-20140037718-A1 | TRANSDERMAL PAIN GEL | LUTZ GEORGE W (US) | 2014-02-06 | — | — | US | claimed |
| US-20100226972-A1 | TRANSDERMAL PAIN GEL | LUTZ GEORGE W | 2010-09-09 | — | — | US | claimed |
| EP-4313014-B1 | A METHOD FOR THE PRODUCTION OF GASTRORETENTIVE COMPACT MATRICES FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND COMPACT MATRICES THUS OBTAINED | UNIV DEGLI STUDI GENOVA (IT) | 2026-01-28 | — | — | EP | disclosed |
| CN-119776295-A | Olefin reductase, coding gene, vector, engineering bacteria and application thereof | 浙江工业大学 | 2025-04-08 | — | — | CN | disclosed |
| US-20240299304-A1 | A METHOD FOR THE PRODUCTION OF GASTRORETENTIVE COMPACT MATRICES FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND COMPACT MATRICES THUS OBTAINED | UNIVERSITA DEGLI STUDI DI GENOVA (IT) | 2024-09-12 | — | — | US | disclosed |
| CN-117561055-A | Method for producing a gastroretentive dense matrix for the controlled release of active substances and dense matrix obtained | 热那亚大学 | 2024-02-13 | — | — | CN | disclosed |
| EP-4313014-A1 | A METHOD FOR THE PRODUCTION OF GASTRORETENTIVE COMPACT MATRICES FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND COMPACT MATRICES THUS OBTAINED | Università degli Studi di Genova (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-114685298-B | Method for synthesizing baclofen based on photocatalytic migration strategy | 兰州大学 | 2023-10-24 | — | — | CN | disclosed |
| US-7250043-B2 | Catheter for modification of agent formulation | DURECT CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070167932-A1 | Local concentration management system | DURECT CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20040068251-A1 | Catheter for modification of agent formulation | DURECT CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-6629969-B2 | Catheter for modification of agent formulation | DURECT CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030032942-A1 | Local concentration management system | DURECT CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-20030028174-A1 | Catheter for modification of agent formulation | DURECT CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |